Home › Research › Drug development
Statins for the prevention of dementia
McGuinness B, Craig D, Bullock R, Passmore P.. The Cochrane database of systematic reviews, 2009-04-15
Topic: Risk, prevention and care in population studies
Plain-language summary
Main results Two trials were identified with 26,340 participants; HPS 2002 and PROSPER 2002. Mean total cholesterol 5.9 mmol/l, LDL cholesterol 3.4 mmol/l at study entry with mean reduction in LDL cholesterol of 1.0 mmol/l in simvastatin treated patients compared to placebo in HPS 2002. Mean total cholesterol 5.7 mmol/l, LDL cholesterol 3.8 mmol/l at study entry with mean reduction in LDL cholesterol of 1.02 mmol/l in pravastatin treated patients compared to placebo in PROSPER 2002. Cognitive function declined at the same rate in both treatment groups in PROSPER 2002, there was no significant difference between pravastatin treated and placebo groups in performance on letter digit codes, picture word learning test, Stroop and Mini Mental State Examination.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009). Statins for the prevention of dementia. The Cochrane database of systematic reviews. https://doi.org/10.1002/14651858.cd003160.pub2
Vancouver
McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. The Cochrane database of systematic reviews. 2009. doi:10.1002/14651858.cd003160.pub2. PMID: 19370582.
BibTeX
@article{mcguinness2009-19370582,
author = {McGuinness, B. and Craig, D. and Bullock, R. and Passmore, P.},
title = {{Statins for the prevention of dementia}},
journal = {The Cochrane database of systematic reviews},
year = {2009},
doi = {10.1002/14651858.cd003160.pub2},
pmid = {19370582},
url = {https://doi.org/10.1002/14651858.cd003160.pub2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Main results Two trials were identified with 26,340 participants; HPS 2002 and PROSPER 2002.
- Mean total cholesterol 5.9 mmol/l, LDL cholesterol 3.4 mmol/l at study entry with mean reduction in LDL cholesterol of 1.0 mmol/l in simvastatin treated patients compared to placebo in HPS 2002.
- Mean total cholesterol 5.7 mmol/l, LDL cholesterol 3.8 mmol/l at study entry with mean reduction in LDL cholesterol of 1.02 mmol/l in pravastatin treated patients compared to placebo in PROSPER 2002.
- Cognitive function declined at the same rate in both treatment groups in PROSPER 2002, there was no significant difference between pravastatin treated and placebo groups in performance on letter digit codes, picture word learning test, Stroop and Mini Mental State Examination.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Participants5,804
- Effect size23.7%; 24.2%
- Evidence strengthHigh
How this study scored 81/100
Published in a leading specialty journal, and it is a meta-analysis pooling many studies. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 47 of the 58 points we could judge it on, which is 81 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Cochrane database of systematic reviews) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 3 / 4 | 5,804 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19370582) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 47 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 47 of the 58 points we could judge it on is 81 out of 100. |
| Total | 81 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “statins”
10 studies in the library carry the topic tag “statins”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 10 tagged studies.